is the Clibanarius tricolor, or the blue-legged hermit crab, which has been recorded to live in symbiosis in the Caribbean and Indo-Pacific Regions. This crab uses the surface of the anemone as a “microhabitat” and is protected from the anemone's harmful toxins by removable coverings on the surface of their bodies. Another largely studied endosymbiont is the anemone shrimp. Hayes et al. reported cohabitation of sun anemones by Periclimenes rathbunae, also called sun anemone shrimp, in a random manner that may be directly influenced by anemone size in the West Indies. In a further study, Periclimenes yucatanicus, or “spotted-cleaner shrimp”, were additionally observed in symbiosis with Stichodactyla helianthus in the Florida Bay. Toxin production Like many other sea anemones, S. helianthus excretes a variety of toxins that can serve different purposes such as prey capture, protection and defense against predators. In specific, Sticholysin II (St II) is a cytolysin that has been extracted from the nematocysts of Sun Anemones and further examined by method of immunoperoxidase staining (structure included- Pennington et al.). Basulto et al. concludes that Sticholysin II functions in exclusive roles within the anemone's physiology, including predation and digestion. Another study revealed a similar lysin, known as Sticholysin I (St I), suggesting multiple isoforms of the same lysin. These two Sticholysins are further expanded on by Alvarez et al., whereas they are described as “pore-forming toxins”. S. helianthus are also capable of producing polypeptide neurotoxins. Kem et al. reports a study where a newly found variant of actiniid neurotoxin, namely Sh 1, was extracted from S. helianthus and yielded genetic similarity to toxin II of Heteractic paumotensis., another species in family Stichodactylidae. Medical application S. helianthus shows a variety of promising applications in the medical field due to its toxin-producing capability. ShK-186, a peptide inhibitor, is a toxin that has been previously implemented in clinical trials for its potential treatment of autoimmune diseases. It has been further developed into an “investigational drug”, known as Dalazatide, in which it targets the disease-causing cells corresponding to ailments including type 1 diabetes, lupus erythematosus and multiple sclerosis The aforementioned cytolysins, St I and St II, have also shown pharmacological potential in studies with guinea pig models, with direct implications on neural and cardiac activity. Due to its capability of protease inhibition, ShPI-1 is another toxin with medical potential. This toxin is a “non-specific inhibitor” and provides a variant with “increased biomedical